PWC
GILD icon

Pathfinder Wealth Consulting’s Gilead Sciences GILD Stock Holding History

Pathfinder Wealth Consulting’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,813
Closed -$253K – 54
2026
Q1 		$253K Sell
1,813
-547
-23% -$76.6K 0.16% 137
2025
Q4 		$290K Buy
+2,360
New +$287K 0.18% 113

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pathfinder Wealth Consulting's GILD Position: Q2 2026 in Review

Pathfinder Wealth Consulting sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,813 shares — an estimated $253K sold.

Pathfinder Wealth Consulting first reported a position in GILD in Q4 2025 and held it in 2 quarters. The position peaked at $290K in Q4 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Pathfinder Wealth Consulting reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Pathfinder Wealth Consulting sold 1,813 Gilead Sciences shares in Q2 2026, an estimated $253K.
  • Pathfinder Wealth Consulting first reported a position in Gilead Sciences in Q4 2025 and held it in 2 quarters.
  • Pathfinder Wealth Consulting's Gilead Sciences position peaked at $290K in Q4 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Pathfinder Wealth Consulting's 13F filing for Q2 2026.